Drug Profile


Alternative Names: P 0005672; P 005672; WC-3035

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Actavis; Allergan
  • Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Rosacea

Most Recent Events

  • 27 Mar 2017 Allergan plans to file an NDA with the US FDA for Acne vulgaris in the second-half of 2017
  • 27 Mar 2017 Efficacy and adverse events data from two pivotal phase III trials in Acne vulgaris released by Allergan and Paratek Pharmaceuticals
  • 01 Feb 2017 Allergan completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA (PO, tablets) (NCT02320149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top